Ratings Bausch Health Companies Inc. Toronto S.E.

Equities

BHC

CA0717341071

Delayed Toronto S.E. Other stock markets 01:10:52 2024-05-21 pm EDT			5-day change	1st Jan Change
8.89 ^CAD	-3.58%		-8.73%	-16.37%

May. 17	Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	CI
May. 15	RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's profit outlook over the next few years is a strong asset.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company does not generate enough profits, which is an alarming weak point.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
BAUSCH HEALTH COMPANIES INC.	-16.37%	2.38B	-
ELI LILLY AND COMPANY	+37.77%	705B	C+
NOVO NORDISK A/S	+32.82%	583B	B
JOHNSON & JOHNSON	-3.68%	364B	C+
MERCK & CO., INC.	+20.18%	332B	B-
ABBVIE INC.	+4.90%	291B	C+
ASTRAZENECA PLC	+16.64%	238B	B+
ROCHE HOLDING AG	-4.13%	210B	A+
NOVARTIS AG	+10.63%	209B	B-
AMGEN INC.	+8.75%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes